Gabriella M Anic1,2, Demetrius Albanes2, Sabine Rohrmann3, Norma Kanarek4,5, William G Nelson4,5,6, Gary Bradwin7, Nader Rifai7, Katherine A McGlynn2, Elizabeth A Platz4,6,8, Alison M Mondul9. 1. Cancer Prevention Fellowship Program, Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA. 2. Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA. 3. Division of Chronic Disease Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland. 4. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA. 5. Department of Environmental Health Sciences, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 6. Department of Urology and the James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 7. Department of Laboratory Medicine, Harvard Medical School and Children's Hospital, Boston, MA, USA. 8. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 9. Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA.
Abstract
BACKGROUND: Recent literature suggests that high circulating vitamin D may increase prostate cancer risk. Although the mechanism through which vitamin D may increase risk is unknown, vitamin D concentration could influence circulating sex steroid hormones that may be associated with prostate cancer; an alternate explanation is that it could be associated with prostate-specific antigen (PSA) concentration causing detection bias. OBJECTIVE: We examined whether serum vitamin D concentration was associated with sex steroid hormone and PSA concentrations in a cross-sectional analysis of men in the National Health and Nutrition Examination Surveys (NHANES). DESIGN: Testosterone, oestradiol, sex hormone-binding globulin (SHBG), androstanediol glucuronide, and 25-hydroxyvitamin D (25(OH)D) were measured in serum from men aged 20 and older participating in NHANES III (n = 1315) and NHANES 2001-2004 (n = 318). Hormone concentrations were compared across 25(OH)D quintiles, adjusting for age, race/ethnicity, body fat percentage, and smoking. PSA concentration was estimated by 25(OH)D quintile in 4013 men from NHANES 2001-2006. RESULTS: In NHANES III, higher testosterone (quintile (Q) 1 = 17·2, 95% confidence interval (CI) = 16·1-18·6; Q5 = 19·6, 95% CI = 18·7-20·6 nmol/l, P-trend = 0·0002) and SHBG (Q1 = 33·8, 95% CI = 30·8-37·0; Q5 = 38·4, 95% CI = 35·8-41·2 nmol/l, P-trend = 0·0005) were observed with increasing 25(OH)D. Similar results were observed in NHANES 2001-2004. PSA concentration was not associated with serum 25(OH)D (P-trend = 0·34). CONCLUSION: Results from these nationally representative studies support a positive association between serum 25(OH)D and testosterone and SHBG. The findings support an indirect mechanism through which vitamin D may increase prostate cancer risk, and suggest the link to prostate cancer is not due to PSA-detection bias.
BACKGROUND: Recent literature suggests that high circulating vitamin D may increase prostate cancer risk. Although the mechanism through which vitamin D may increase risk is unknown, vitamin D concentration could influence circulating sex steroid hormones that may be associated with prostate cancer; an alternate explanation is that it could be associated with prostate-specific antigen (PSA) concentration causing detection bias. OBJECTIVE: We examined whether serum vitamin D concentration was associated with sex steroid hormone and PSA concentrations in a cross-sectional analysis of men in the National Health and Nutrition Examination Surveys (NHANES). DESIGN:Testosterone, oestradiol, sex hormone-binding globulin (SHBG), androstanediol glucuronide, and 25-hydroxyvitamin D (25(OH)D) were measured in serum from men aged 20 and older participating in NHANES III (n = 1315) and NHANES 2001-2004 (n = 318). Hormone concentrations were compared across 25(OH)D quintiles, adjusting for age, race/ethnicity, body fat percentage, and smoking. PSA concentration was estimated by 25(OH)D quintile in 4013 men from NHANES 2001-2006. RESULTS: In NHANES III, higher testosterone (quintile (Q) 1 = 17·2, 95% confidence interval (CI) = 16·1-18·6; Q5 = 19·6, 95% CI = 18·7-20·6 nmol/l, P-trend = 0·0002) and SHBG (Q1 = 33·8, 95% CI = 30·8-37·0; Q5 = 38·4, 95% CI = 35·8-41·2 nmol/l, P-trend = 0·0005) were observed with increasing 25(OH)D. Similar results were observed in NHANES 2001-2004. PSA concentration was not associated with serum 25(OH)D (P-trend = 0·34). CONCLUSION: Results from these nationally representative studies support a positive association between serum 25(OH)D and testosterone and SHBG. The findings support an indirect mechanism through which vitamin D may increase prostate cancer risk, and suggest the link to prostate cancer is not due to PSA-detection bias.
Authors: Gerald L Andriole; David G Bostwick; Otis W Brawley; Leonard G Gomella; Michael Marberger; Francesco Montorsi; Curtis A Pettaway; Teuvo L Tammela; Claudio Teloken; Donald J Tindall; Matthew C Somerville; Timothy H Wilson; Ivy L Fowler; Roger S Rittmaster Journal: N Engl J Med Date: 2010-04-01 Impact factor: 91.245
Authors: Sharif B Mohr; Edward D Gorham; John E Alcaraz; Christopher J Kane; Caroline A Macera; J Kellogg Parsons; Deborah L Wingard; Cedric F Garland Journal: Anticancer Res Date: 2011-09 Impact factor: 2.480
Authors: Sarah B Peskoe; Corinne E Joshu; Sabine Rohrmann; Katherine A McGlynn; Sarah J Nyante; Gary Bradwin; Adrian S Dobs; Norma Kanarek; William G Nelson; Elizabeth A Platz Journal: Prostate Date: 2015-04-28 Impact factor: 4.104
Authors: Xinqing Deng; Yiqing Song; JoAnn E Manson; Lisa B Signorello; Shumin M Zhang; Martha J Shrubsole; Reid M Ness; Douglas L Seidner; Qi Dai Journal: BMC Med Date: 2013-08-27 Impact factor: 8.775
Authors: Di Zhao; Pamela Ouyang; Ian H de Boer; Pamela L Lutsey; Youssef M K Farag; Eliseo Guallar; David S Siscovick; Wendy S Post; Rita R Kalyani; Kevin L Billups; Erin D Michos Journal: Maturitas Date: 2016-11-29 Impact factor: 4.342
Authors: Armin Zittermann; Jana B Ernst; Sylvana Prokop; Uwe Fuchs; Jens Dreier; Joachim Kuhn; Cornelius Knabbe; Heiner K Berthold; Ioanna Gouni-Berthold; Jan F Gummert; Jochen Börgermann; Stefan Pilz Journal: Eur J Nutr Date: 2018-03-15 Impact factor: 5.614
Authors: Shakira M Nelson; Orestis A Panagiotou; Gabriella M Anic; Alison M Mondul; Satu Männistö; Stephanie J Weinstein; Demetrius Albanes Journal: Int J Epidemiol Date: 2016-08-14 Impact factor: 7.196
Authors: Justin M Roberts; Rebeca San Martin; D Badrajee Piyarathna; James G MacKrell; Guilherme V Rocha; Jeffery A Dodge; Cristian Coarfa; Venkatesh Krishnan; David R Rowley; Nancy L Weigel Journal: Oncotarget Date: 2017-07-04
Authors: Christian Trummer; Stefan Pilz; Verena Schwetz; Barbara Obermayer-Pietsch; Elisabeth Lerchbaum Journal: Endocr Connect Date: 2018-02-15 Impact factor: 3.335
Authors: John S Fitzgerald; Joanna Orysiak; Patrick B Wilson; Joanna Mazur-Różycka; Zbigniew Obminski Journal: Biol Sport Date: 2018-03-31 Impact factor: 2.806